[Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis].
BACKGROUND
Almotriptan has proven to be more efficacious and tolerable than ergotamine plus caffeine but is more expensive, thus raising the question about its cost-efficacy.


METHODS
The course of migraine attacks during 24 hours treated with almotriptan and ergotamine plus caffeine was modelled with a decision tree, using efficacy data from a recent randomized, double-blind clinical trial comparing the two drugs. Costs were calculated from the social perspective (including indirect costs due to absenteeism and loss of productivity) and from the Spanish National Health System (NHS) perspective (only including drug costs). The impact on quality of life was estimated using utilities assigned in the literature to different health states of migraine patients.


RESULTS
Treatment response was 57.7% for patients treated with almotriptan vs. 44.5% with ergotamine plus caffeine. Sustained pain-free status was achieved by 20.3% vs. 11.5%. Working days lost due to absenteeism and reduced productivity amounted to 0.24 vs. 0.38 days. Quality of life during attacks was estimated at an average utility of 0.548 vs. 0.422. From the NHS perspective, incremental costs per attack treated with almotriptan vs. ergotamine plus caffeine was euro 5.05, rendering an incremental cost-efficacy ratio of euro38.26 per additional response, euro57.39 per additional complete response, and euro14,709 per quality- adjusted life-year gained. From the social perspective almotriptan saved euro7.50 vs. ergotamine plus caffeine.


CONCLUSIONS
Almotriptan can be considered cost-efficacious vs. ergotamine plus caffeine from the NHS perspective and is the dominant option (both more efficacious and more economical) from the social perspective.
Universidad Autónoma de Barcelona, Bellaterra.
J
J
Slof
J M
JM
Láinez
A
A
Comas
J
J
Heras
D018712:Analgesics, Non-Narcotic / Q000191:economics / Q000627:therapeutic use; D002110:Caffeine / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis / Q000191:economics; D004878:Ergotamine / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000191:economics; D017060:Patient Satisfaction / Q000191:economics; D011788:Quality of Life; D016896:Treatment Outcome; D014363:Tryptamines / Q000191:economics / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D014363:Tryptamines; C409045:almotriptan; D002110:Caffeine; D004878:Ergotamine